Trump's surgeon general nominee delays confirmation hearing after going into labor, prolonging vacancy in the role.
Novo Nordisk makes a bold $9B bid to acquire Metsera, a U.S. biotech firm, in a bid to outpace Pfizer's existing $4.9B deal and regain leadership in the competitive obesity drug market.
S&P Global reports strong Q3 results, raises full-year guidance, and plans strategic divestitures amid market volatility.
Trump's surgeon general nominee delays confirmation hearing after going into labor, prolonging vacancy in the role.
Novo Nordisk makes a bold $9B bid to acquire Metsera, a U.S. biotech firm, in a bid to outpace Pfizer's existing $4.9B deal and regain leadership in the competitive obesity drug market.
S&P Global reports strong Q3 results, raises full-year guidance, and plans strategic divestitures amid market volatility.